Barclays maintains Pacific Biosciences at Underweight, raises price target to $2 from $1.25
Barclays kept its Underweight rating on Pacific Biosciences but raised its price target to $2 from $1.25, suggesting a 21.6% downside from the last close of $2.55. The increase represents a 60.0% rise in the target price.
How this was made

The 30-second read
Why it matters
The downgrade could trigger short covering or further downside if investors align with the new target.
Market read
Analyst target change is the primary catalyst, likely influencing short-term price action.
What to watch
Potential upcoming data releases or partnership announcements could offset the bearish target.
Background
Barclays' research note updates its valuation for Pacific Biosciences, a small-cap biotech focused on DNA sequencing technology.
Ticker impact
Barclays raised its price target for Pacific Biosciences to $2 from $1.25, implying a downside from the current price.
likely pressure as the market prices in the lower target
The new target is below the recent close, indicating a bearish view from a major broker.
Market effects
May affect sentiment in the biotech sequencing sector.
Limited to US biotech investors.
Low
Counterpoint
Some investors may view the target raise as a buying opportunity if they believe the market overreacted to recent volatility.
Key entities
- AnalystBarclays
Equity research firm providing the price target update.
- CompanyPacific Biosciences
US-listed biotech company (ticker PACB).


